1BT Stock Chart & Stats
€1.09
-€0.18(-4.57%)
At close: 4:00 PM EDT
€1.09
-€0.18(-4.57%)
Day’s Range― - ―
52-Week Range€0.18 - €15.30
Previous CloseN/A
Volume0.00
Average Volume (3M)288.00
Market Cap
€3.08M
Enterprise Value€28.67M
Total Cash (Recent Filing)€5.52M
Total Debt (Recent Filing)€17.25M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)577.48
Shares Outstanding19,908,590
10 Day Avg. Volume373
30 Day Avg. Volume288
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€71.41Price Target Upside6451.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Equity BaseVery low leverage and a large equity base provide Enlivex with greater solvency and financial flexibility than its operating profile alone would suggest. This balance-sheet strength can help support clinical development, absorb operating volatility, and preserve strategic options over the next several quarters.
Focused Clinical Capital AllocationThe cost-reduction plan narrows spending around a defined Phase 2b milestone while reducing workforce and executive compensation. A more focused operating model could extend capital runway and improve execution discipline if the company delivers the expected six-month topline readout.
Regulatory And Clinical SupportFDA RMAT designation and encouraging early clinical results strengthen the development case for Allocetra in knee osteoarthritis. These milestones may facilitate regulatory interaction and improve the program’s strategic relevance, although substantial clinical development remains before commercialization.
Bears Say
No Revenue And Ongoing LossesEnlivex remains an R&D-stage company without reported revenue or operating profitability, so its business model is not yet self-sustaining. Continued dependence on external capital and successful clinical development leaves financial performance highly sensitive to trial outcomes and funding conditions.
Persistent Cash BurnNegative operating and free cash flow show that Enlivex continues to consume cash to fund operations rather than generate internal financing. Even though burn improved from earlier periods, ongoing cash use can constrain clinical investment and increase reliance on debt or equity financing.
Crypto-linked Balance-sheet RiskThe shift toward substantial digital-asset holdings makes reported earnings and balance-sheet values more dependent on volatile financial instruments rather than therapeutic operations. This reduces earnings quality and adds tax, derivative, and strategic risk alongside the company’s clinical-development exposure.
Enlivex News
1BT FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was €0.18 and its highest was €15.30 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is €3.08M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 180 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -€0.018 earnings per share for the quarter.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 19,908,590 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -€0.018 in its last earnings report. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in DE:1BT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
1BT Stock 12 Month Forecast
Average Price Target
€71.41
▲(6451.71% Upside)